Taysha Gene Therapies Cash Flow Statement
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Taysha Gene Therapies free cash flow
In fiscal 2025, Taysha Gene Therapies generated -$93.1 million of operating cash flow and spent $738,000 on capital expenditures. That left free cash flow of -$93.8 million, a free-cash-flow margin of -960.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Taysha Gene Therapies cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -109.00M | -89.30M | -111.57M | -166.01M | -174.52M | -60.01M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 1.15M | 1.25M | 1.37M | 1.17M | 492.00K | 9.00K |
| Stock-Based Compensation | 13.30M | 13.10M | 7.91M | 18.04M | 18.18M | 3.35M |
| Change in Working Capital | -11.66M | -11.05M | -11.73M | 27.84M | 11.13M | -4.62M |
| Operating Cash Flow | -93.09M | -81.22M | -73.02M | -88.39M | -117.04M | -30.73M |
| Capital Expenditures | -738.00K | -374.00K | -3.87M | -20.62M | -15.30M | -82.00K |
| Investing Cash Flow | -604.00K | -363.00K | -7.35M | -24.93M | -21.55M | -9.08M |
| Financing Cash Flow | 274.59M | 76.68M | 136.39M | 52.10M | 39.08M | 291.06M |
| Net Change in Cash | 180.90M | -4.90M | 56.02M | -61.22M | -99.51M | 251.25M |
| Free Cash Flow | -93.83M | -81.60M | -76.89M | -109.01M | -132.35M | -30.81M |
This table shows 6 annual periods of Taysha Gene Therapies's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TSHA's reporting calendar. What is a cash flow statement?